Drug Design and Discovery in Alzheimer’s Disease


Atta-ur-Rahman, Mohammad Iqbal Choudhary

DOI: 10.2174/97816080582281150101
eISBN: 978-1-60805-822-8, 2014
ISBN: 978-1-60805-823-5
ISSN: 1574-0889 (Print)
ISSN: 2212-1064 (Online)

Indexed in: Book Citation Index, Science Edition, BIOSIS Previews, Scopus, EMBASE, EBSCO, Ulrich's Periodicals Directory.

“Frontiers in Drug Design and Discovery” is an Ebook series devoted to publishing the latest and the most important advances in drug d...[view complete introduction]
US $
Buy Personal eBook
Order Library eBook
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

Towards Small Molecules as Therapies for Alzheimer’s Disease and Other Neurodegenerative Disorders

- Pp. 199-290 (92)

Omar Aziz, Roland W. Bürli, David F. Fischer, Julie Frearson and Michael D. Wall


Neurodegenerative diseases caused by hereditary or idiosyncratic neuronal dysfunction share some phenotypic commonalities. Intracellular aggregation of proteins, metal dyshomeostasis, generic loss of synaptic connectivity all lead to gradual decline of cognitive or motor neuronal function as patients descend into a clinically symptomatic state. Though significant progress has been made in our understanding of neurological disorders in the past decade, it has yet to translate into therapeutic advancements in disease treatment. </p><p> We have chosen to focus this review on Alzheimer’s disease (AD) to highlight the main disease modifying mechanisms shared in common with the Huntington’s (HD) and Parkinson’s disease (PD) phenotypes, specifically, the aggregation of amyloid-β (Aβ) phospho-tau (p-tau), mutant huntingtin (mHtt) and α -synuclein (α-syn) proteins, respectively. We highlight a number of approaches used in pre-clinical drug discovery to identify clinical tools. In addition, we describe a number of less explored alternative hypotheses which have demonstrated good (pre)clinical evidence for a potential therapeutic intervention. </p><p> In particular, for AD, we will review the main concepts which have driven drug discovery research in the recent past and for each molecular target, we summarize a rationale and available validation data with commentary on relevant chemical matter and structural biology, then discuss advanced pre-clinical and clinical compounds.

Purchase Chapter  Book Details


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science